查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918108

亨廷顿舞蹈症治疗市场－2026-2031年预测

Huntington's Disease Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计亨廷顿舞蹈症治疗市场将从 2025 年的 9.35 亿美元成长到 2031 年的 21.29 亿美元，复合年增长率为 14.7%。

亨廷顿舞蹈症治疗市场预计将稳定成长，这主要得益于针对这种复杂神经退化性疾病的研发活动显着活性化。市场格局的特点是从对症治疗转向疾病修正治疗，大量科学研究和资金资源正投入先进治疗方法中。

市场扩张的关键驱动力在于强大且不断成长的在临床实验药物管线。临床试验格局正在快速变化，涌现出多种新型治疗方法。这些方法包括针对特定病理路径（例如异常补体系统活性）的单株抗体，以及目前处于中后期临床试验阶段的先进细胞疗法，例如干细胞疗法。临床研究的蓬勃发展反映了各方为识别和检验可能改变疾病进展的治疗方法而做出的共同努力。

同时，基因疗法已成为一个极具前景且发展迅速的领域。多个基因疗法候选药物正处于临床开发阶段，其作用机制主要集中在抑制亨丁顿舞蹈症突变基因的表达。美国FDA的简审类等项目正在加速这些创新治疗方法的监管审批流程，旨在加速研发和审查进程。这些计画从早期试验进入后期研究，标誌着治疗产品线已日趋成熟，并成为市场的重要成长动力。

该疾病日益普遍，加之人们对超越对症治疗的先进治疗方法的需求不断增长，迫切需要有效的治疗方法。这种需求是推动製药和生技公司投资高风险、高回报研发的根本动力。显然，研发重点在于开发能够改变疾病根本病理的干预措施，而这正是目前最大的未满足需求，也是最大的市场机会。

北美地区预计将成为关键市场，这得益于其高疾病负担、完善且资金充足的临床研究基础设施以及积极的法规环境。该地区是活跃的研发中心，许多成熟的製药和生物技术公司正在进行大量的临床试验。这种科学研究和商业性活动的集中度正在巩固北美作为全球市场成长主要驱动力的地位。

预计亚太地区在预测期内也将呈现强劲成长。这一增长预计将受到各国主导为改善公民健康和加强医疗基础设施而不断加大投入的推动。然而，该地区的市场成长可能会受到竞争激烈的学名药市场及其相关专利挑战的限制，这可能会影响品牌药的商业策略。

总而言之，亨廷顿舞蹈症治疗市场正经历着以科学创新和向缓解疾病治疗方法策略转型为特征的动态变革时期。随着基因疗法、单株抗体和干细胞疗法在临床试验中不断推进，有利的法规结构和日益增长的投资为市场扩张创造了有利环境。专注于开发治疗方法，是塑造市场未来发展轨迹及其满足重大未满足需求潜力的核心范式。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 亨廷顿舞蹈症治疗市场（依类型划分）

  • 介绍
  • 药物治疗
    • Tetrabenazine
    • Tetrabenazine
    • 其他的
  • 治疗
    • 物理治疗
    • 语言治疗
    • 疾病修正治疗

6. 亨廷顿舞蹈症治疗市场（依给药途径划分）

  • 介绍
  • 注射
  • 口服

7. 亨廷顿舞蹈症治疗市场（以最终用户划分）

  • 介绍
  • 医院
  • 专科诊所
  • 其他的

8. 各地区亨廷顿舞蹈症治疗市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Teva Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
  • Bausch Health Companies Inc
  • Neurocrine Biosciences, Inc.
  • Prilenia Therapeutics
  • Novartis AG
  • Lupin Limited
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd
  • Atalanta Therapeutics
  • F. Hoffmann-La Roche AG

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615578

Huntington's Disease Treatment Market is expected to grow at a 14.7% CAGR, achieving USD 2.129 billion in 2031 from USD 0.935 billion in 2025.

The Huntington's disease treatment market is positioned for steady growth, driven by a marked intensification in research and development activities aimed at addressing this complex neurodegenerative disorder. The market landscape is characterized by a shift from symptomatic management toward the pursuit of disease-modifying therapies, with significant scientific and financial resources being channeled into advanced therapeutic modalities.

A primary catalyst for market expansion is the robust and expanding pipeline of investigational treatments. The clinical trial landscape is rapidly evolving, featuring a diverse array of novel therapeutic approaches. These include monoclonal antibodies designed to target specific pathological pathways, such as aberrant complement system activity, and advanced cell-based interventions like stem cell therapies currently in mid-to-late-stage clinical studies. This proliferation of clinical research reflects a concerted effort to identify and validate treatments that can alter the disease's progression.

Concurrently, gene therapy has emerged as a particularly promising and rapidly advancing segment. Multiple gene therapy candidates are progressing through clinical development, with mechanisms of action focused on silencing the expression of the mutant huntingtin gene. The regulatory pathway for these innovative treatments is being facilitated by designations such as the U.S. FDA's Fast Track, which aims to accelerate the development and review process. The progression of these programs from early-stage trials toward later-phase studies underscores a significant maturation in the therapeutic pipeline and represents a substantial growth vector for the market.

The increasing prevalence of the disease, coupled with a growing demand for advanced therapeutic options beyond symptomatic care, is creating a pressing need for effective treatments. This demand is a fundamental driver, incentivizing pharmaceutical and biotechnology companies to invest in high-risk, high-reward research endeavors. The focus is squarely on developing interventions that can modify the underlying disease pathology, a area where the highest unmet medical need and, consequently, the greatest market opportunity reside.

Geographically, North America is anticipated to be a significant marketplace, a status attributed to its high disease burden, well-established and well-funded clinical research infrastructure, and proactive regulatory environment. The region is a hub for active research and development, with numerous clinical trials initiated by both established pharmaceutical firms and biotechnology companies. This concentration of scientific and commercial activity solidifies North America's role as a primary driver of global market growth.

The Asia-Pacific region is also predicted to exhibit robust growth during the forecast period. This expansion is expected to be fueled by increasing government initiatives aimed at improving population health and enhancing healthcare infrastructure. However, market growth in this region may be tempered by a competitive generic drug landscape and associated patent challenges, which can influence the commercial strategy for branded therapeutics.

In summary, the Huntington's disease treatment market is in a dynamic state of transition, defined by scientific innovation and a strategic pivot towards disease-modifying interventions. The advancement of gene therapies, monoclonal antibodies, and stem cell treatments through clinical trials, supported by a conducive regulatory framework and growing investment, is creating a fertile environment for market expansion. The focus on developing therapies that can fundamentally alter the disease course, rather than merely alleviate symptoms, represents the central paradigm shaping the market's future trajectory and its potential to address a significant unmet medical need.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Huntington's Disease Treatment Market Segmentation:

  • By Type
  • Medication
  • Tetrabenazine
  • Deutetrabenazine
  • Others
  • Therapy
  • Physical Therapy
  • Speech Therapy
  • Disease Modifying Therapy
  • By Route of Administration
  • Injectable
  • Oral
  • By End-User
  • Hospitals
  • Specialty Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. HUNTINGTON'S DISEASE TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Medication
    • 5.2.1. Tetrabenazine
    • 5.2.2. Deutetrabenazine
    • 5.2.3. Others
  • 5.3. Therapy
    • 5.3.1. Physical Therapy
    • 5.3.2. Speech Therapy
    • 5.3.3. Disease Modifying Therapy

6. HUNTINGTON'S DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Injectable
  • 6.3. Oral

7. HUNTINGTON'S DISEASE TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Clinics
  • 7.4. Others

8. HUNTINGTON'S DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Teva Pharmaceutical Industries Ltd.
  • 10.2. H. Lundbeck A/S
  • 10.3. Bausch Health Companies Inc
  • 10.4. Neurocrine Biosciences, Inc.
  • 10.5. Prilenia Therapeutics
  • 10.6. Novartis AG
  • 10.7. Lupin Limited
  • 10.8. Hikma Pharmaceuticals PLC
  • 10.9. Dr. Reddy's Laboratories Ltd
  • 10.10. Atalanta Therapeutics
  • 10.11. F. Hoffmann-La Roche AG

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations